In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age

To the Editor,

A well-known risk factor for food allergies is childhood eczema or atopic dermatitis (AD).1 Even the non-lesional skin of AD subjects with food allergies has morphologic changes characteristic of a distinct endotype.2 Allergen exposure from house dust and/or contamination on caregivers hands on inflamed skin may provoke the release of alarmins resulting in inflammatory Th2-skewing.3

In a recent study, we followed the evolution of serum epitope-specific (ses-)IgE and ses-IgG₄ antibodies in a subset of 341 infants at risk for peanut allergy (LEAP trial). Children in the early peanut consumption group acquired a different ses-IgE repertoire compared with avoiders that developed allergy, suggesting that oral ingestion promotes immunologic tolerance.4,5 We sought to further evaluate whether antibody profiles could be an early indicator of allergic epicutaneous sensitization to peanut.

Peanut allergy and sensitization status were defined at 5 years of age into the following mutually exclusive groups: Allergic, Sensitized, and Non-allergic. In this sub-cohort, 38/172 (22%) Avoidance Group and 75/169 (44%) Consumption Group children developed peanut allergy. Peanut sensitization was observed in 59/172 (34%) Avoiders and 94/169 (56%) Consumers. The remaining 150 (44%) were Non-allergic and equally represented (75/172 and 75/169) in the Avoidance and Consumption Groups, respectively. Detailed antibody profiling was published previously5 by these outcomes, and this analysis further stratifies by the presence of eczema at 2.5 years of age. Since together with egg allergy, eczema was an inclusion criterion, 335 (98%) participants had eczema at 4–11 months. By 2.5 years, 297 (87%) children still had eczema, defined as the SCORAD >0 (Table E1). Levels of ses-IgE and ses-IgG₄ against 64 sequential epitopes from Ara h 1, 2, and 3 allergens were measured at 4–11 months, 1, 2.5, and 5 years of age (see Supplementary Material). Even though sample sizes in the “no eczema” groups were small (Table E2), several interesting observations could be found.

None of the Non-allergic children and Sensitized Avoiders had increases in ses-IgE levels, regardless of their eczema status (Figures E1A and E2). However, the expansion of ses-IgE to a distinct set of epitopes on Ara h 1 and Ara h 2 proteins was observed only among Allergic Avoiders with eczema (magenta rectangles in Figure 1A). Although the sample size was very small, none of the peanut allergic avoiders without eczema (n = 3) had ses-IgE to those epitopes at a 2.5-year timepoint but did develop ses-IgE to some of the epitopes of the eczema group by 5 years.

Instead, Allergic Avoiders without eczema developed increases in ses-IgE to a different set of Ara h 1 epitopes (cyan rectangles, Figure 1A,B). Since eczema severity can change over time, we confirmed observed trends by modeling SCORAD with selected ses-IgEs (Figure E3). These differences were only observed in IgE to specific epitopes and not to peanut extract or component proteins (Figure 1C, Figure E1).

Interestingly, IgE epitopes in the eczema group had distinct protein folding structures and biochemical characteristics, that is, less thermal stability, higher potential for creating bonds with other proteins, and position preference in alpha-helix bends (Figure 1D,E, Table E3). As for the ses-IgG₄, Allergic Avoiders with and without eczema had similar profiles (Figure 2). Non-allergic Avoiders without eczema had higher ses-IgG₄ levels at 5 years in the majority (92%) of ses-IgG₄. Among Sensitized Avoiders and all Consumers, the presence of eczema was associated with more rapid increases in ses-IgG4 levels at 5 years. These differences were not observed in peanut-specific IgG₄.

Overall, peanut allergic avoiders with eczema had distinct ses-IgE profiles, potentially suggesting a different route of allergic sensitization. The trends observed should be interpreted with caution. Eczema was a key LEAP inclusion criterion, thus limiting the number of non-eczema subjects and potentially influencing the results.
FIGURE 1  Ses-IgE association with eczema status in Allergic Avoiders. (A) Barplots representing changes in ses-IgE from 4–11m to 1, 2.5, and 5 years (grey if not significant), stars show significance by eczema status. Magenta boxes—"eczema," cyan—"no eczema" group epitopes. (B) Lineplots showing estimated marginal means of epitopes with the largest log₂ fold-changes and peanut-specific IgE (C). Colored stars represent change from 4–11m and dark blue stars—significance by eczema status ($p < .05^*, .01^{**}, <.001^{***}$). (D) Epitopes position on the crystal structures of respective proteins. (E) Significantly different biochemical properties, colored if higher in either "eczema" or "non-eczema" groups.

FIGURE 2  Ses-IgG4 association with eczema. Lineplots showing estimated marginal means and 95% confidence intervals (CI) of IgG4 specific to selected epitopes (normalized MFI) and peanut extract (log_{10} of mg/ml) by early peanut exposure and 5-year allergy status at all timepoints. Colored stars represent change from 4–11m and dark blue stars—significance by eczema status ($p < .05^*, .01^{**}, <.001^{***}$).
AUTHOR CONTRIBUTIONS
The study was conceptualized by G.L., G.T., M.S.F., and H.A.S. Sample acquisition, data curation, analysis and visualization were carried out by M.S., H.T.B., and M.S.F. Original draft was written by M.S., M.S.F, and H.S. All authors reviewed, edited, and approved the manuscript.

FUNDING INFORMATION
This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565, NO1-AI-15416, UM1AI109565, HHSN272200800029C, and UM2AI117870; the David H. and Julia Koch Research Program in Food Allergy Therapeutics; and AllerGenis LLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

CONFLICT OF INTEREST
Dr. Suprun receives research support from NIH-NIAID (UCSD U19 AI070535-16) and has provisional patent application for egg-BBEA, this technology is filed through Mount Sinai and licensed to AllerGenis, LLC. Henry Bahnson has received research support from the NIAID/National Institutes of Health (contract nos. HHSN272200800029C and UM2AI117870) and reports contract work paid to institution, Benaroya Research Institute, from DBV Technologies, MYOR https://www.myorcare.com/, King's College London, and Stanford University; and additional salary support paid by King's College London and Stanford University. Dr. du Toit has received research support from the NIAID (NO1-AI-15416 [contract] and UM1AI109565 [grant], covering salary) and the UK Food Standards Agency; has received a contribution to NIAID contract/grant from the Food Allergy Research & Education; has received a contribution to KCL Division of Asthma Allergy & Lung Biology from Medical Research Council (MRC) & Asthma UK Centre; has received the Biomedical Research Centre (BRC) award to Guy's and St Thomas' National Health Service (NHS) Foundation from the UK Department of Health through the National Institute for Health Research (NIHR); and has received support for pediatric allergy clinical trial's unit from the National Peanut Board. Dr. Lack has received research support from the NIAID (NO1-AI-15416 [contract] and UM1AI109565 [grant]), and UK Food Standards Agency; is on the DBV Technologies scientific advisory board; has received a contribution to NIAID contract/grant from Food Allergy Research and Education; has received a contribution to KCL Division of Asthma Allergy & Lung Biology from MRC & Asthma UK Centre; has received the BRC award to Guy's and St Thomas' NHS Foundation from the UK Department of Health through NIHR; has received support for pediatric allergy clinical trial's unit from the National Peanut Board; has received discounted Bamba peanut snack from Osem; and has stock/stock options in DBV Technologies. Dr. Suárez-Fariñas received research funding to Mount Sinai by a grant from AllerGenis LLC. Dr. Sampson reports non-financial support from AllerGenis LLC during the conduct of the study; grants from Immune Tolerance Network; NIAID/NIH, personal fees from N-Fold Therapeutics, other from DBV Technologies (employee: part-time CSO), outside the submitted work; Mount Sinai has licensed the BBEA technology to AllerGenis LLC. Dr. Sampson, serves as an unpaid Board of Directors member and advisor to AllerGenis LLC.

ORCID
Maria Suprun 1 https://orcid.org/0000-0001-7350-4021
Henry T. Bahnson 2
George du Toit 3 https://orcid.org/0000-0002-321-2928
Mayte Suarez-Farinas 1
Hugh A. Sampson 1

1 Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 Benaroya Research Institute, Seattle, Washington, USA
3 St. Thomas Hospital & King's College, London, UK

CORRESPONDENCE
Hugh A. Sampson, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, New York, NY 10029-6574, USA. Email: hugh.sampson@mssm.edu

REFERENCES

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.